Navigation Links
PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
Date:5/15/2013

eginning olaparib, as did two (25 percent) of the prostate patients. Overall survival at one year was 41 percent for the pancreatic cancer patients, and 50 percent for the prostate cancer patients.

For patients with breast and ovarian cancer, the study confirmed the previously reported activity of olaparib, although tumors treated in this study were much more advanced than in prior studies. For example, in 193 patients with ovarian cancer in whom cisplatin was no longer effective for controlling advanced disease, 31 percent had partial or complete tumor regression on olaparib, and 64 percent were alive at one year. Among 62 patients with metastatic breast cancer patients who had already received at least three chemotherapy regimens, 13 percent responded to new therapy and 45 percent of patients were alive at one year.

The authors found that treatment with olaparib is very well-tolerated. The most commonly reported side effects were mild to moderate fatigue and nausea (each experienced by 59 percent of patients), and transient episodes of vomiting (37 percent). Seventeen percent of patients experienced anemia, and four percent of patients suffered side effects that led to discontinuation of therapy.

As of January 2013, 33 patients remained on the study.

"This study underscores a new paradigm in cancer therapy. We can better fashion treatments for our patients based on a personalized assessment of the genetic factors underlying the cancer," Domchek says. "PARP inhibitors such as olaparib represent the most promising new treatment for individuals suffering from cancer based on inherited BRCA1 and BRCA2 gene mutations."

The results will be presented by lead author Bella Kaufman, MD, from Sheba Medical Center in Tel Hashomer, Israel, in the Tumor Biology poster session from 8 a.m. to noon on Monday, June 3, 2013 in S102 McCormick Place.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
2. Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment
3. New inhibitors of elusive enzymes promise to be valuable scientific tools
4. Team solves birth and migration mysteries of cortexs powerful inhibitors, chandelier cells
5. MDC and FMP researchers identify edema inhibitor
6. Genetic survey of endangered Antarctic blue whales shows surprising diversity
7. University of Houston study shows BP oil spill hurt marshes, but recovery possible
8. Weakness can be an advantage in surviving deadly parasites, a new study shows
9. Study shows unified process of evolution in bacteria and sexual eukaryotes
10. Sexual reproduction brings long-term benefits, study shows
11. UCSB study shows forest insects and diseases arrive in US via imported plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Elsevier, a world-leading provider of scientific, technical and ... Research Management Society (ARMS), recognized the academic research ... Scopus Young Researcher of the Year Awards. , ... National Convention Centre and in conjunction with the ... representing Australia,s and New Zealand,s scientific community. Guest ...
(Date:9/18/2014)... entire lives nestling in the protective tentacles of host ... sometimes travel hundreds of kilometres across the open ocean. ... has been predicted, this is the first time that ... has been observed. , Dr Steve Simpson, Senior Lecturer ... of Exeter, and colleagues from the Australian Research Council ...
(Date:9/17/2014)... EC-FP5 four-year project, delivering its first release in 2004. ... in several EC projects, as a part of the ... BON), to increase the general awareness of the work ... dissemination of the Fauna Europaea results, the ... e-Publishing tools to prepare data papers for all 56 ...
Breaking Biology News(10 mins):Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... Wash. -- A new study reveals how pollution causes ... Appearing in the Proceedings of the National Academy ... long-standing debate and reveal how pollution plays into climate ... the accuracy of weather and climate models. Researchers ...
... that protect it from insect damage has been grown in the ... are derived from a bacterium called Bacillus thuringiensis , these ... has been highly effective against the European corn borer, it has ... documented to show resistance to the Bt proteins. In a new ...
... impairment is a transitional stage between normal aging ... this transformation have yet to be studied. Dr. ... Technology, China constructed brain networks using resting-state functional ... (normal controls, patients with early mild cognitive impairment, ...
Cached Biology News:The lingering clouds 2The lingering clouds 3Scientists offer recommendations for delaying resistance to Bt corn in western corn rootworm 2
(Date:9/18/2014)... Pennsylvanie, 18 septembre 2014 Mapi, ... en 1974, a été depuis 40 ans ... évaluations cliniques traditionnelles par des évaluations recentrées ... sur les impacts économiques des traitements. ... A cours d,une récente conférence ...
(Date:9/18/2014)... expensive. Now a team led by an engineer at ... designs that will let scientists slash the cost of ... , Syringe pumps are used to dispatch precise amounts ... in a reaction. They can also cost hundreds or ... team of Michigan Tech students published the library of ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... , the latest addition to Clinovo’s CRO Partnership Program. ... (CRO) Program, Clinovo further expands its global reach to ... training, we are now able to build studies on ... can also rely on Clinovo to fully support the ...
(Date:9/17/2014)... 17, 2014 A long-term retrospective study ... irradiation (APBI) via interstitial brachytherapy suggests that women ... nodes could be suitable to receive the treatment. ... place these patients in the "unsuitable" category for ... ASTRO meeting, Beaumont Health System,s Peter Y. ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Doing science just got cheaper -- and faster 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4
... DUBLIN, Ireland, January 9 Azur Pharma ... the exclusive U.S. marketing rights,for Niravam(R) (alprazolam ... Kemstro(TM) (baclofen,orally disintegrating tablets) and Fluxid(TM) (famotidine ... terms were not,disclosed. , ...
... The IN VIVO Blog , which provides news, insights and ... a Deal of the Year for 2008 -- ... than 2,500 reader votes were cast in this inaugural competition, ... the 13 nominees selected by The IN VIVO Blog,s writers ...
... MATK ) announced today that it will be ... The conference is being held January 14-15, 2009 at ... Point, California. Peter L. Buzy, Chief Financial Officer, and ... 2009 at 1:25 PM PT.A live audio webcast of Martek,s ...
Cached Biology Technology:Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2The IN VIVO Blog Selects First Annual 'Deal of the Year' 2